PARENT ABSTRACT - SUBPROJECT ABSTRACT NOT AVAILABLE The long-range goal of this Program Project is to develop viral vector-based gene transfer strategies for treating genetic and acquired cardiopulmonary disorders. To this end, a group of investigators with diverse, yet complementary interdisciplinary interests and expertise has established an integrated research effort that is underscored by a common interest inpracticalapplications of gene therapy. A major focus of the Programis the development of improved methods of gene transfer. Four of the components (Subproject 3, Subproject 4, Subproject and Pilot 2) are primarily focused onthe development of vectors suitable for transduction of terminally differentiated cells. These include two stable expression vectors, Adeno-associated virus (AAV, Subproject 3) and lentivirus (subproject 4), as wellas two transient expression vectors, adenovirus (Ad, Subproject 5) and the entomopoxvirus (EPV, Pilot 2). In each case, the efforts are directed at identifying and circumventing obstacles to the practical applicationof gene therapy, most of which are rooted in the basic biology of the individual virus upon which each vector system is based. Along with the vector development components, there is a strong emphasis on the development of new animal models, including the development of knock-out mouse models for monogenic cardiac (Subproject 1) and pulmonary (Pilot 1, Subproject 2) disorders, and a transgenic model for AAV integration (Subproject 1). The utilization of established models of hypertension and acute lung injury are likewise pivotal for Subprojects 6 and 5, respectively. The program also will investigate the applications of these vector systems to three cardiopulmonary disorders: alpha-1-antitrypsin deficiency (alpha 1AT, Subproject 2), acid maltase deficiency (GAA, Subproject 1) and hypertension (Subproject 6). This will be done by targeting vectors to muscle (Subprojects 1 and 2) and vascular endothelium (Subprogject 6). Additionally, the Program has established a Vector Core Laboratory (Core B) which will supply vectors of uniform and reproducible quality to all subprojects, and investigate improved methods of generating recombinant AAV (rAAV) and adenovirus (Ad) vectors. The Vector Core will also serve as a mechanism to insure rapid exchange of information among all subprojects. Finally, an Administrative Core (Core A) will insure centralized fiscal management and oversight for the subprojects and pilot/feasibility projects.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL059412-04
Application #
6353084
Study Section
Project Start
2000-09-15
Project End
2001-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
2000
Total Cost
$269,466
Indirect Cost
Name
University of Florida
Department
Type
DUNS #
073130411
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Smith, Barbara K; Martin, A Daniel; Lawson, Lee Ann et al. (2017) Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity. Exp Neurol 287:216-224
Salganik, Maxim; Aydemir, Fikret; Nam, Hyun-Joo et al. (2014) Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J Virol 88:1071-9
Elder, Melissa E; Nayak, Sushrusha; Collins, Shelley W et al. (2013) B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 163:847-54.e1
ElMallah, Mai K; Falk, Darin J; Lane, Michael A et al. (2012) Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9. Hum Gene Ther Methods 23:148-56
Salganik, Maxim; Venkatakrishnan, Balasubramanian; Bennett, Antonette et al. (2012) Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J Virol 86:11877-85
Qiu, Kai; Falk, Darin J; Reier, Paul J et al. (2012) Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice. Mol Ther 20:21-7
Wu, Ke; Li, Shoudong; Bodhinathan, Karthik et al. (2012) Enhanced expression of Pctk1, Tcf12 and Ccnd1 in hippocampus of rats: Impact on cognitive function, synaptic plasticity and pathology. Neurobiol Learn Mem 97:69-80
Petrs-Silva, Hilda; Dinculescu, Astra; Li, Qiuhong et al. (2011) Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 19:293-301
DeRuisseau, Lara R; Fuller, David D; Qiu, Kai et al. (2009) Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci U S A 106:9419-24
Clément, Nathalie; Knop, David R; Byrne, Barry J (2009) Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum Gene Ther 20:796-806

Showing the most recent 10 out of 19 publications